E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
intubated and mechanically ventilated pediatric subjects that require sedation in
an intensive care setting for a minimum of 6 hours but not to exceed 24 hours.
Subjects eligible for enrollment are 12 months to < 24 months of age |
|
E.1.1.1 | Medical condition in easily understood language |
intubated and mechanically ventilated pediatric subjects that require sedation in
an intensive care setting for a minimum of 6 hours but not to exceed 24 hours.
|
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To define the pharmacokinetic (PK) profile of dexmedetomidine (DEX) administered
as an intravenous (IV) loading dose followed by a continuous IV infusion in pediatric
subjects 12 months through <24 months of age.
2. To define the pharmacodynamic (PD) profile of dexmedetomidine (DEX)
administered as an intravenous (IV) loading dose followed by a continuous IV
infusion in pediatric subjects 12 months through <24 months of age. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate safety in subjects 12 months through <24 months of age |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Subject is 12 months to < 24 months of age at screening.
2. Subject is intubated and mechanically ventilated in an intensive care setting and is
anticipated to require a minimum of 6 hours of continuous IV sedation.
3. Subject has adequate renal function, defined as:
• Serum creatinine ≤ 1.0 mg/dL
4. The subject’s parent(s) or legal guardian(s) must voluntarily sign and date the
informed consent document approved by the Institutional Review Board. |
|
E.4 | Principal exclusion criteria |
Pediatric subjects with neurological conditions that prohibit an evaluation of
sedation such as:
• Diminished consciousness from increased intracranial pressure
• Extensive brain surgery (surgery requiring intracranial pressure monitor)
• Diminished cognitive function per Principal Investigator (PI) discretion
• Subjects with immobility from neuromuscular disease or continuous infusion
of neuromuscular blocking agents.
2. Subjects with second degree or third degree heart block unless subject has a
permanent pacemaker or pacing wires are in situ.
3. Subjects who have hepatic impairment as defined by a SGPT/ALT >90 U/L at the
time of Screening.
4. Subjects who have hypotension, based on repeat assessments within 15 minutes
preceding the start of study drug, defined as:
• SBP < 70 mmHg
5. Pre-existing bradycardia based on repeated assessments within 15 minutes
preceding the start of study drug, defined as:
• HR < 70 bpm
6. Subject who have acute thermal burns involving more than 15 percent total body
surface area.
7. Subjects who have a known allergy to dexmedetomidine, MDZ or fentanyl.
8. Subject who has received dexmedetomidine within 24 hours prior to the start of
study drug.
9. Subjects with a life expectancy that is < 72 hours.
10. Subjects that are expected to have hemodialysis (continuous hemofiltration),
peritoneal dialysis or extracorporeal membrane oxygenation (ECMO) treatments
within 48 hours prior to the start of study drug or during the duration of the study.
11. Subjects who have been treated with α-2 agonists/antagonists within two weeks
(see Appendix B).
12. Subjects with a spinal cord injury above T5.
13. Subjects who have received another investigational drug as part of an
investigational drug study within the past 30 days.
14. Subjects who, in the opinion of the investigator, may not be able to comply with
the safety monitoring requirements of this clinical study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To define the pharmacokinetic (PK) profile of dexmedetomidine (DEX) administered as an
intravenous (IV) loading dose followed by a continuous IV infusion in pediatric subjects 12 months
through < 24 months of age.
2. To define the pharmacodynamic (PD) profile of DEX administered as an IV loading dose followed
by a continuous IV infusion in pediatric subjects 12 months through < 24 months of age |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Each subject received a loading dose of DEX over 10 minutes followed by the appropriate continuous
infusion maintenance dose of DEX for a minimum of 6 but not more than 24 hours (including the loading
dose time). |
|
E.5.2 | Secondary end point(s) |
To evaluate the safety of DEX in subjects 12 months through < 24 months of age. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Each subject received a loading dose of DEX over 10 minutes followed by the appropriate continuous
infusion maintenance dose of DEX for a minimum of 6 but not more than 24 hours (including the loading
dose time). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Pharmacokinetic and Pharmacodynamic study Subjects Aged 12 months through < 24 months |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |